4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 25
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Ms. Linda F. Powers J.D. | Chairperson, CEO, President, CFO & Chief Accounting Officer | 849.09k | N/A | 1956 |
Dr. Alton L. Boynton Ph.D. | Founder, Chief Scientific Officer, Secretary & Director | 344.23k | N/A | 1945 |
Dr. Marnix L. Bosch M.B.A., Ph.D. | Chief Technical Officer | 416.38k | 67.93k | 1959 |
Mr. Leslie J. Goldman | Senior VP & General Counsel | 665.5k | N/A | 1945 |
Mr. David Innes | Vice President of Investor Relations | N/A | N/A | N/A |
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.